849 related articles for article (PubMed ID: 25204288)
21. Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents.
Zhao J; Feng SS
Nanomedicine (Lond); 2015 Jul; 10(14):2199-228. PubMed ID: 26214357
[TBL] [Abstract][Full Text] [Related]
22. Advances in siRNA delivery in cancer therapy.
Singh A; Trivedi P; Jain NK
Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):274-283. PubMed ID: 28423924
[TBL] [Abstract][Full Text] [Related]
23. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
24. A Dual Targeting Dendrimer-Mediated siRNA Delivery System for Effective Gene Silencing in Cancer Therapy.
Dong Y; Yu T; Ding L; Laurini E; Huang Y; Zhang M; Weng Y; Lin S; Chen P; Marson D; Jiang Y; Giorgio S; Pricl S; Liu X; Rocchi P; Peng L
J Am Chem Soc; 2018 Nov; 140(47):16264-16274. PubMed ID: 30346764
[TBL] [Abstract][Full Text] [Related]
25. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery.
Ma X; Zhao Y; Ng KW; Zhao Y
Chemistry; 2013 Nov; 19(46):15593-603. PubMed ID: 24123533
[TBL] [Abstract][Full Text] [Related]
26. Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology.
Shu D; Li H; Shu Y; Xiong G; Carson WE; Haque F; Xu R; Guo P
ACS Nano; 2015 Oct; 9(10):9731-40. PubMed ID: 26387848
[TBL] [Abstract][Full Text] [Related]
27. siRNA-Conjugated Nanoparticles to Treat Ovarian Cancer.
Halbur C; Choudhury N; Chen M; Kim JH; Chung EJ
SLAS Technol; 2019 Apr; 24(2):137-150. PubMed ID: 30616494
[TBL] [Abstract][Full Text] [Related]
28. Targeted Delivery of siRNA Therapeutics using Ligand Mediated Biodegradable Polymeric Nanocarriers.
Cho KS; Hong SJ; Ahn MH; Pal S; Choung PH; Sangshetti J; Arote RB
Curr Pharm Des; 2018; 24(16):1788-1800. PubMed ID: 29962332
[TBL] [Abstract][Full Text] [Related]
29. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA.
Taratula O; Garbuzenko OB; Chen AM; Minko T
J Drug Target; 2011 Dec; 19(10):900-14. PubMed ID: 21981718
[TBL] [Abstract][Full Text] [Related]
30. The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells.
Cao N; Cheng D; Zou S; Ai H; Gao J; Shuai X
Biomaterials; 2011 Mar; 32(8):2222-32. PubMed ID: 21186059
[TBL] [Abstract][Full Text] [Related]
31. Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
Kim GH; Won JE; Byeon Y; Kim MG; Wi TI; Lee JM; Park YY; Lee JW; Kang TH; Jung ID; Shin BC; Ahn HJ; Lee YJ; Sood AK; Han HD; Park YM
Drug Deliv; 2018 Nov; 25(1):1394-1402. PubMed ID: 29890852
[TBL] [Abstract][Full Text] [Related]
32. Polypeptide cationic micelles mediated co-delivery of docetaxel and siRNA for synergistic tumor therapy.
Zheng C; Zheng M; Gong P; Deng J; Yi H; Zhang P; Zhang Y; Liu P; Ma Y; Cai L
Biomaterials; 2013 Apr; 34(13):3431-8. PubMed ID: 23375952
[TBL] [Abstract][Full Text] [Related]
33. Co-Delivery of Epirubicin and siRNA Using Functionalized Mesoporous Silica Nanoparticles Enhances In vitro and In vivo Drug Efficacy.
Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Abnous K; Malaekeh-Nikouei B
Curr Drug Deliv; 2016; 13(7):1176-1182. PubMed ID: 26718488
[TBL] [Abstract][Full Text] [Related]
34. Delivery of RNAi-Based Therapeutics for Bone Regeneration.
Malcolm DW; Wang Y; Overby C; Newman M; Benoit DSW
Curr Osteoporos Rep; 2020 Jun; 18(3):312-324. PubMed ID: 32394316
[TBL] [Abstract][Full Text] [Related]
35. Delivery of small interfering RNAs by nanovesicles for cancer therapy.
Pengnam S; Plianwong S; Yingyongnarongkul BE; Patrojanasophon P; Opanasopit P
Drug Metab Pharmacokinet; 2022 Feb; 42():100425. PubMed ID: 34954489
[TBL] [Abstract][Full Text] [Related]
36. Codelivery of anticancer drugs and siRNA by mesoporous silica nanoparticles.
Hanafi-Bojd MY; Ansari L; Malaekeh-Nikouei B
Ther Deliv; 2016 Sep; 7(9):649-55. PubMed ID: 27582236
[TBL] [Abstract][Full Text] [Related]
37. Nanocarrier Mediated siRNA Delivery Targeting Stem Cell Differentiation.
Fernandes F; Kotharkar P; Chakravorty A; Kowshik M; Talukdar I
Curr Stem Cell Res Ther; 2020; 15(2):155-172. PubMed ID: 31789134
[TBL] [Abstract][Full Text] [Related]
38. The Daniel K. Inouye College of Pharmacy Scripts: Targeted Nanocarrier Based Systems for the Treatment of Lung Cancer.
Youngren-Ortiz SR; Chougule MB
Hawaii J Med Public Health; 2017 Nov; 76(11):318-325. PubMed ID: 29164017
[TBL] [Abstract][Full Text] [Related]
39. Recent progress in nanotechnology for cancer therapy.
Tang MF; Lei L; Guo SR; Huang WL
Chin J Cancer; 2010 Sep; 29(9):775-80. PubMed ID: 20800018
[TBL] [Abstract][Full Text] [Related]
40. Gene/paclitaxel co-delivering nanocarriers prepared by framework-induced self-assembly for the inhibition of highly drug-resistant tumors.
Wang C; Guan W; Peng J; Chen Y; Xu G; Dou H
Acta Biomater; 2020 Feb; 103():247-258. PubMed ID: 31846802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
